2-(1-Methylpropyl)thiazole
Common Name: |
2-(1-Methylpropyl)thiazole |
IUPAC Name: |
2-butan-2-yl-1,3-thiazole |
Molecular Formula: |
C5H10O2S |
SMILES: |
CCC(C)C1=NC=CS1 |
Inchi: |
1S/C7H11NS/c1-3-6(2)7-8-4-5-9-7/h4-6H,3H2,1-2H3 |
Inchi Key: |
MHJSWOZJMPIGJQ-UHFFFAOYSA-N |
Cas No: |
18277-27-5 |
Name |
Value |
Lipinski Violations |
0 |
Ghose Violations |
3 |
Veber Violations |
0 |
Egan Violations |
0 |
Muegge Violations |
1 |
Name |
Value |
Molecular Weight (g/mol) |
134.20 |
Mass (g/mol) |
141.061 |
Molar Refractivity |
35.36 |
Net Charge |
|
HBD |
|
HBA |
2 |
Rt Bonds |
3 |
Rings |
1 |
TPSA |
65.10 |
Hetero Atoms |
2 |
Heavy Atoms |
8 |
Aromatic Heavy Atoms |
0 |
Melting Point (°C) |
|
Boiling Point (°C@760.00mm Hg) |
174.00 to 175.00 |
Vapor Pressure (mmHg@25.00 °C) |
1.473 |
Vapor Density (Air =1) |
|
Fraction Csp3 |
0.80 |
LogP |
2.657 |
iLOGP |
1.88 |
XLOGP3 |
1.20 |
WLOGP |
0.87 |
MLOGP |
0.89 |
ESOL Log S |
-1.23 |
ESOL Solubility (mg/ml) |
7.9 |
ESOL Solubility (mol/l) |
0.059 |
ESOL Class: esol_class |
Very soluble |
Ali Log S |
-2.16 |
Ali Solubility (mg/ml) |
0.92 |
Ali Solubility (mol/l) |
0.01 |
Ali Class |
Soluble |
Silicos-IT LogSw |
-0.88 |
Silicos-IT Solubility (mg/ml) |
17.9 |
Silicos-IT Solubility (mol/l) |
0.13 |
Silicos-IT Class |
Soluble |
Name |
Value |
GI Absorption |
High |
BBB Permeable |
0 |
PgP Substrate |
0 |
Log Kp (cm/s) |
-6.27 |
Bioavailability Score |
0.55 |
Caco2 |
1 |
Human Intestinal Absorption |
1 |
Plasm Protein Binding |
0.743 |
CYP1A2 Inhibitor |
0 |
CYP2C19 Inhibitor |
0 |
CYP2C9 Inhibitor |
0 |
CYP2D6 inhibitor |
0 |
CYP3A4 inhibitor |
0 |
Ames mutagenesis |
0 |
Acute Oral Toxicity |
2.802 |
Carcinogenicity (Binary) |
0 |
Carcinogenicity (Trinary) |
Warning |
Eye Irritation |
1 |
Hepatotoxicity |
0 |
Androgen Receptor Binding |
0 |
Aromatase Binding |
0 |
Estrogen Receptor Binding |
0 |
Glucocorticoid Receptor Binding |
0 |
Thyroid Receptor Binding |
0 |
BRCP inhibitor |
0 |
BSEP inhibitor |
0 |
OATP1B1 inhibitor |
1 |
OATP1B3 inhibitor |
1 |
OATP2B1 inhibitor |
0 |
OCT1 inhibitor |
0 |
OCT2 inhibitor |
0 |